1-乙氧基-3-(甲基磺酰基)苯 | 700348-34-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-乙氧基-3-(甲基磺酰基)苯
• 英文名称: 1-Ethoxy-3-(methylsulfonyl)benzene
• 英文别名: 1-ethoxy-3-methylsulfonylbenzene
• CAS: 700348-34-1
• 化学式: C₉H₁₂O₃S
• mdl: MFCD18825171
• 分子量: 200.258
• InChiKey: IXZVTHKTGRBFFP-UHFFFAOYSA-N

物化性质

• 沸点：
  361.4±34.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-乙氧基苯硼酸 、 sodium methansulfinate 在 copper diacetate 、 4 Angstroem MS 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 以89%的产率得到1-乙氧基-3-(甲基磺酰基)苯
  参考文献：
  名称：

  由硼酸和亚磺酸盐温和高效地合成芳基砜的新方法

  摘要：

  据报道，一种新的由硼酸和亚磺酸盐有效，温和地制备砜的方法。由乙酸铜介导的交叉偶联反应以优异的产率获得了多种砜。

  DOI：

  10.1016/j.tetlet.2004.02.127

文献信息

• METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150148542A1

  公开（公告）日：2015-05-28

  The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及根据本文所描述和定义的一般式（I）制备取代三唑吡啶化合物的方法，以及用于制备所述化合物的中间体化合物。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Baldwin Robert Ian

  公开号：US20070142373A1

  公开（公告）日：2007-06-21

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2, R 19, R 20, and R 34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新型化合物(I)的公式或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，制备它们的过程，含有它们的配方以及它们在治疗炎症性疾病中的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。
• Small Molecules That Covalently Modify Transthyretin
  申请人：Kelly Jeffery W.

  公开号：US20140336254A1

  公开（公告）日：2014-11-13

  A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ε-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.

  本发明揭示了一种共价动力稳定剂化合物家族，它们选择性地和共价地与显著的血浆蛋白转甲状腺素反应，而不是其他4000多种人类血浆蛋白。考虑到的化合物对应于以下公式I的结构，其中各种取代基在内部定义，并与转甲状腺素四聚体内的四个Lys-15 ε-氨基基团之一或两个发生化学选择性反应。晶体结构证实了化合物亚结构和结合酰胺键的结合方向。与非共价对应物相比，共价转甲状腺素动力稳定剂表现出优越的淀粉样抑制效力，并抑制与淀粉样生成相关的细胞毒性。
• SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS
  申请人：Bayer Intellectual Property GmbH

  公开号：US20150210683A1

  公开（公告）日：2015-07-30

  The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R 1 , R 2 , R 3 , R 4 , and R 5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及一般式（I）的取代三唑吡啶化合物，其中R1、R2、R3、R4和R5如说明书和权利要求书中所述，涉及制备该化合物的方法，涉及包含该化合物的制药组合物和组合物，涉及使用该化合物制造用于治疗或预防疾病的制药组合物，以及在制备该化合物中有用的中间化合物。